Asana Biosciences, LLC

Smithkline Beecham Corporation

Endo Pharmaceuticals Inc.

Curadev Pharma Pvt Ltd

Smithkline Corporation

Abs Development 1, Inc.

Ansana Biosciences, LLC

Glaxosmithkline LLC

Endo Pharmaceuticals Solutions Inc.

Scott Kevin Thompson

Roger Astbury Smith

Aranapakam Mudumbai Venkatesan

Ashis K Saha

Tony Priestley

Sanjeeva P Reddy

Daniel F Veber

Sunil Kumar Panigrahi

Raghava Reddy Kethiri

Purushottam M Dewang

Mrinal Kundu

Stacie Marie Halbert

Chandrika Mulakala

Gurulingappa Hallur

Dennis Shinji Yamashita

Saumitra Sengupta

Vijay Potluri

Lara Kallander

Mrinalkanti Kundu

Chun Ma

Suvadeep Nath

Tyler M John

Vijay Kumar Nyavanandi

Prabhakara Rao Nadipalli

Subramanya Hosahalli

James S Frazee

Nicholas James Laping

Michael J Neeb

Joseph Marino

Sonali Rudra

Timothy Francis Gallagher

Maxwell David Cummings

Robert W Marquis, Jr

Sandeep Gupta

Srinivas Nanduri

Joseph P Marino, Jr

Hosahalli Subramanya

Kamal Kishore Kapoor

Thomas Joseph Carr

Renee Louise DesJarlais

Yu Ru

Ajita Bhat

Ritesh Shrivastava

Sandip Middya

Mallesham Bejugam

Monali Banerjee

Arjun Surya

Hye-Ja Oh

Dharmendra B Yadav

Jack Hwekwo Yen

Mohd Zainuddin

Natarajan Mahalingam

Sushil Raina

Katherine L Widdowson

John Duncan Elliott

Hui-Yin Li

Jack Dale Leber

Bheemashankar A Kulkarni

Dennis Lee

Carl Henry Behrens

Chandregowda Venkateshappa

Rajendra Kristam

Rajesh Devraj

John Jeffrey McAtee

Robert A Stavenger

Tram H Hoang

Veejendra K Yadav

Ramesh Mullangi

Yigang He

Subramanya Hoshalli

David G Washburn

Srinivas Kasibhatla

Dhanalakshmi Sivanandhan

Ning Wang

Arun Kuma Hajra

Dipanwita Chatterjee

Marlys Hammond

Latisha C Johnson

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

P2X3 and/or P2X2/3 compounds and methods

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

P2Xand/or P2Xcompounds and methods

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. 

[object Object]

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxy-genase.

Inhibitors of the kynurenine pathway

Growing community of inventors

Phoenixville, PA, United States of America

Scott Kevin Thompson